ZA917170B - Novel antibodies for treatment and prevention of infection in animals and man - Google Patents

Novel antibodies for treatment and prevention of infection in animals and man

Info

Publication number
ZA917170B
ZA917170B ZA917170A ZA917170A ZA917170B ZA 917170 B ZA917170 B ZA 917170B ZA 917170 A ZA917170 A ZA 917170A ZA 917170 A ZA917170 A ZA 917170A ZA 917170 B ZA917170 B ZA 917170B
Authority
ZA
South Africa
Prior art keywords
infection
man
animals
prevention
treatment
Prior art date
Application number
ZA917170A
Other languages
English (en)
Inventor
William J Harris
J Harris William
Philip R Tempest
R Tempest Philip
Geraldine Taylor
Taylor Geraldine
Original Assignee
Scotgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotgen Ltd filed Critical Scotgen Ltd
Publication of ZA917170B publication Critical patent/ZA917170B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027Paramyxoviridae, e.g. respiratory syncytial virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2/00Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA917170A 1990-09-11 1991-09-10 Novel antibodies for treatment and prevention of infection in animals and man ZA917170B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019812A GB9019812D0 (en) 1990-09-11 1990-09-11 Novel antibodies for treatment and prevention of infection in animals and man

Publications (1)

Publication Number Publication Date
ZA917170B true ZA917170B (en) 1992-07-29

Family

ID=10682003

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA917170A ZA917170B (en) 1990-09-11 1991-09-10 Novel antibodies for treatment and prevention of infection in animals and man

Country Status (12)

Country Link
EP (1) EP0548190A1 (pt)
JP (1) JPH06501152A (pt)
KR (1) KR930702519A (pt)
AU (1) AU654827B2 (pt)
CA (1) CA2091335A1 (pt)
GB (1) GB9019812D0 (pt)
IE (1) IE913177A1 (pt)
MX (1) MX9101046A (pt)
NZ (1) NZ239728A (pt)
PT (1) PT98944B (pt)
WO (1) WO1992004381A1 (pt)
ZA (1) ZA917170B (pt)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992001473A1 (en) * 1990-07-19 1992-02-06 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Improved immunotherapeutic method of preventing or treating viral respiratory tract disease
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
EP0671927B1 (en) * 1992-09-16 2003-01-15 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
AU689489B2 (en) * 1993-07-30 1998-04-02 Oravax, Inc Monoclonal IgA antibody against respiratory syncytial virus
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
WO1995031546A1 (en) * 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
AU7075496A (en) 1995-09-18 1997-04-09 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
EP1378525A3 (en) 1996-06-07 2004-01-14 Neorx Corporation Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
PT970206E (pt) 1997-01-27 2008-10-28 Ludwig Inst Cancer Res Ácidos nucleicos lage-1 associados a tumores
PT1003501E (pt) 1997-04-02 2005-07-29 Brigham & Womens Hospital Utilizacao de um agente para reduzir o risco de doencas cardiovasculares
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
ATE407949T1 (de) 1998-12-30 2008-09-15 Beth Israel Hospital Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
AU5632500A (en) 1999-06-30 2001-01-31 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
EP2267029B1 (en) 1999-09-03 2016-06-15 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents
CN1402782A (zh) 1999-10-19 2003-03-12 路德维哥癌症研究院 Mage-a12抗原肽及其应用
JP2003523957A (ja) * 1999-12-23 2003-08-12 アイシーエヌ・ファーマシューティカルズ・インコーポレイテッド 組成物、並びにl−ヌクレオシド、l−ヌクレオチドおよびそれらのアナログの製造法
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DK2336359T3 (en) 2002-05-09 2016-05-30 Brigham & Womens Hospital 1L1RL-1 as cardiovascular disease marker
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2004210936C1 (en) 2003-02-11 2010-12-02 Takeda Pharmaceutical Company Limited Diagnosis and treatment of Multiple Sulfatase Deficiency and other using a Formylglycine Generating Enzyme (FGE)
JP2007504171A (ja) 2003-08-29 2007-03-01 ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド 細胞壊死インヒビター
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
ES2439229T3 (es) 2004-10-06 2014-01-22 The Brigham And Women's Hospital, Inc. Relevancia de niveles logrados de marcadores de inflamación sistémica tras el tratamiento
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1795596A1 (en) 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
DE102005059242A1 (de) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molekulare Marker für eine Tumordiagnose und -therapie
CA2649148C (en) 2006-04-13 2016-08-23 Chugai Seiyaku Kabushiki Kaisha Taurine transporter gene
EP1911851A1 (en) 2006-10-12 2008-04-16 Ganymed Pharmaceuticals AG Compositions and methods for therapy and diagnosis of cancer and cancer metastasis
EP2463304B1 (en) 2007-02-23 2014-04-30 The United States of America as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that neutralize anthrax toxins
US20100233759A1 (en) 2007-03-15 2010-09-16 Chugai Seiyaku Kabushiki Kaisha Method for production of polypeptide
MX2010001319A (es) 2007-08-07 2010-06-01 Chugai Pharmaceutical Co Ltd Metodo para producir proteinas heterogeneas.
BRPI0818039A2 (pt) 2007-10-15 2014-10-14 Chugai Pharmaceutical Co Ltd Método para produzir uma célula capaz de produção de alto rendimento de heteroproteínas.
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
KR101636086B1 (ko) * 2007-10-24 2016-07-04 추가이 세이야쿠 가부시키가이샤 이종 단백질 제조를 위한 세포 및 그것을 사용한 제조 방법
EP2108701A1 (en) 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
WO2010011697A1 (en) * 2008-07-21 2010-01-28 Immunomedics Inc. Structural variants of antibodies for improved therapeutic characteristics
CN107028969A (zh) 2009-02-20 2017-08-11 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物
EP2221375A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
US8741601B2 (en) 2009-04-22 2014-06-03 Chugai Seiyaku Kabushiki Kaisha Method for producing a cell capable of high-yield production of heteroproteins
EP2249159A1 (en) 2009-04-29 2010-11-10 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
NZ734307A (en) 2009-11-11 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
PL2558499T3 (pl) 2010-04-16 2017-10-31 Biogen Ma Inc Przeciwciała anty-VLA-4
US20130052209A1 (en) * 2010-04-23 2013-02-28 Purdue Research Foundation Protein drug formulations and packages
AU2011248184B2 (en) 2010-05-04 2015-12-17 Board Of Regents, The University Of Texas System Detection and treatment of fibrosis
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
KR102072183B1 (ko) 2011-05-13 2020-02-03 가니메드 파마슈티칼스 게엠베하 클라우딘 6을 발현하는 암 치료용 항체
US20140322723A1 (en) 2011-11-22 2014-10-30 President and Dellows of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
JP2017505124A (ja) 2014-01-24 2017-02-16 ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド ヘンドラ及びニパウイルスのf糖タンパク質に対する抗体
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
WO2017147258A1 (en) 2016-02-23 2017-08-31 Indiana University Research & Technology Corporation Emapii neutralizing antibody limits influenza a virus (iav)-induced lung injury
EP3463482B1 (en) 2016-06-07 2021-10-06 The Brigham and Women's Hospital, Inc. Methods relating to t peripheral helper cells in autoantibody-associated conditions
CN117050176A (zh) 2017-07-31 2023-11-14 豪夫迈·罗氏有限公司 基于三维结构的人源化方法
EP3800999A4 (en) 2018-06-04 2022-06-01 Biogen MA Inc. ANTI-VLA-4 ANTIBODIES WITH REDUCED EFFECTOR FUNCTION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb

Also Published As

Publication number Publication date
AU654827B2 (en) 1994-11-24
MX9101046A (es) 1992-05-04
JPH06501152A (ja) 1994-02-10
CA2091335A1 (en) 1992-03-12
AU8505891A (en) 1992-03-30
EP0548190A1 (en) 1993-06-30
NZ239728A (en) 1995-07-26
IE913177A1 (en) 1992-03-11
PT98944A (pt) 1992-08-31
PT98944B (pt) 1999-02-26
WO1992004381A1 (en) 1992-03-19
KR930702519A (ko) 1993-09-09
GB9019812D0 (en) 1990-10-24

Similar Documents

Publication Publication Date Title
GB9019812D0 (en) Novel antibodies for treatment and prevention of infection in animals and man
ZA932445B (en) Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
SG49658A1 (en) Treatment of condition and disease
GB9203206D0 (en) Treatment of particulate material
GB9014307D0 (en) Method of treatment and compositions therefor
ZA914435B (en) Treatment of disease
FR2663230B1 (fr) Dispositif d'hygiene et de traitement.
GB2263905B (en) Treatment of waste animal materials
EP0540575A4 (en) Human meg-csf protein and methods
IL101749A0 (en) Treatment of mastitis
CS61691A2 (en) Composition for dung-water treatment and method of dung-water treatment
KR960006863B1 (en) Pharmaceutical preparation for treatment of mastitis in animals and humans
EG20171A (en) Treatment of conditions and disease
ZA914464B (en) Method and compositions for treating hiv-type 1 infection
GB9216360D0 (en) Treatment of blood
GB2245475B (en) Improvements in the treatment of animal feeds
RU1833740C (en) Way of treatment and prophylaxis of allergic diseases of reagent type
RU1785692C (en) Preparation for treatment and prophylaxis piglets colibacteriosis
RU1833739C (ru) Cпocoб лeчehия гипepkaлиemии
ZA903993B (en) Treatment of animals
LV5177A3 (lv) Preparats "eridons" govju endometritu profilaksei un arstesanai
LTIP472A (en) Composition for the treatment of infection and disease caused by hepatit b virus
GB9013938D0 (en) Vaccine and treatment for the prevention of type i or juvenile diabetes
NZ233973A (en) Treatment of viral and/or bacterial infections
NZ231322A (en) Treatment of viral and/or bacterial infections